MEDINA Presented Novel Family of Natural Products Antibiotics with Broad Spectrum Against Gram-Negative Pathogens at ICAAC 2013
Fundación MEDINA and Cubist Pharmaceuticals presented research data at ICAAC 2013 on a novel family of natural products antibiotics addressing the emerging threat from Gram-negative pathogens.
Together scientists from Fundación MEDINA and Cubist Pharmaceuticals have discovered a new family of natural molecules that could serve as a scaffold to build next-generations antibiotics. These newly discovered molecules have unprecedented chemical structures and are completely different than antibiotics that have been or are currently being used by doctors. The results from this study were presented in September as a Poster (F1215), at ICCAC 53rd, Denver, Colorado. The data show that these compounds have specific in vitro activity against Gram-negative bacteria such as A. baumannii, P. aeruginosa and E. coli, identified as "superbugs" given their high resistance levels to current antibiotics in the clinic.
This discovery could also mean that many new useful antibiotics remain to be discovered in nature and could be developed to fight against human disease and the emergence of bacterial resistance and super bugs, an increasing public health threat.
This new family of compounds was identified from a crude fermentation extract produced by a filamentous fungus. These results also show that these new molecules are believed to work by interfering with the process by which bacteria build their cells wall.
The new family of molecules was discovered by scientists from Fundacion MEDINA of Granada, Spain, and Cubist Pharmaceuticals Inc. of Lexington, MA, USA, from a joint effort targeted at screening the microbial natural product libraries of Fundación MEDINA looking for new antibiotics to combat infectious diseases.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance